The “imperfect wearable vs. imperfect system” framing is honest and overdue.
But there’s a layer missing from the conversation: marketing is reaching women faster than the clinical evidence is.
By the time a wearable has meaningful validation, women have already been influenced by wellness creators with affiliate links who haven’t read the studies. The data gap isn’t just between device and clinic. It’s between what’s being sold and what’s actually understood.
I work with women who are data rich and context poor. More tracking without the right framing and guidance doesn’t create clarity. It creates a new kind of noise.
Completely agree with this - the growth of social media and influencer marketing is driving an uptake of (not cheap) devices without helping women build a better understanding of their bodies and potential care pathways.
Exactly this, Rachel. And the irony is the women spending $400+ on a ring, stacking supplements and following protocols they found on Instagram, often have the least support in interpreting what any of it is actually telling them. And many don’t look for it either. The influencer already gave them the answer.
@Anastasiya Markvarde and @Anna O'Sullivan, the framing that lands hardest is this: the "imperfect wearable" is competing with an "imperfect system." That resets the entire validation debate. Women have been waiting for a perfect healthcare system that never arrived. A device that adds longitudinal, cycle-anchored data the annual appointment systematically misses isn't a workaround — it's a correction.
The shift from tracking to therapeutic is the category worth watching most closely. INNOVO, Osteoboost, the neuromodulation headbands — these aren't wellness accessories. They're filling clinical gaps that the reimbursement system hasn't caught up to yet. And the Oura data point — 59% women users, fastest growth in their twenties, $11 billion valuation — is the clearest proof that women's health was always the growth driver. The industry just wasn't looking.
The algorithmic suppression layer deserves its own report. These devices face the same ad rejection patterns documented across women's health — which means the innovation is accelerating faster than the visibility infrastructure that would let women find it.
Great article, thanks!
The “imperfect wearable vs. imperfect system” framing is honest and overdue.
But there’s a layer missing from the conversation: marketing is reaching women faster than the clinical evidence is.
By the time a wearable has meaningful validation, women have already been influenced by wellness creators with affiliate links who haven’t read the studies. The data gap isn’t just between device and clinic. It’s between what’s being sold and what’s actually understood.
I work with women who are data rich and context poor. More tracking without the right framing and guidance doesn’t create clarity. It creates a new kind of noise.
Completely agree with this - the growth of social media and influencer marketing is driving an uptake of (not cheap) devices without helping women build a better understanding of their bodies and potential care pathways.
Exactly this, Rachel. And the irony is the women spending $400+ on a ring, stacking supplements and following protocols they found on Instagram, often have the least support in interpreting what any of it is actually telling them. And many don’t look for it either. The influencer already gave them the answer.
@Anastasiya Markvarde and @Anna O'Sullivan, the framing that lands hardest is this: the "imperfect wearable" is competing with an "imperfect system." That resets the entire validation debate. Women have been waiting for a perfect healthcare system that never arrived. A device that adds longitudinal, cycle-anchored data the annual appointment systematically misses isn't a workaround — it's a correction.
The shift from tracking to therapeutic is the category worth watching most closely. INNOVO, Osteoboost, the neuromodulation headbands — these aren't wellness accessories. They're filling clinical gaps that the reimbursement system hasn't caught up to yet. And the Oura data point — 59% women users, fastest growth in their twenties, $11 billion valuation — is the clearest proof that women's health was always the growth driver. The industry just wasn't looking.
The algorithmic suppression layer deserves its own report. These devices face the same ad rejection patterns documented across women's health — which means the innovation is accelerating faster than the visibility infrastructure that would let women find it.